However, in many cases, the results from in vitro tests cannot be simply translated to in vivo conditions
When considering study drug discontinuation or use of rescue medication (trial product estimand results), the weight loss resulting from the use of oral semaglutide was up to 5 kg, while that associated with other active comparators ranged from 0.8 to 3.8 kg, and that associated with placebo ranged from 0.1 to + 0.6 kg [35,36,37,38,39,40]
Dosing for weight loss starts at 0.6 mg per day and is increased in weekly intervals to the full dosage of 3 mg per day, higher than the 1.8-mg dose used for diabetes
Monitor potassium levels, as spironolactone can increase potassium
It is important to note that menstrual disorders are not listed as adverse reactions in the UK Summary of Product Characteristics (SmPCs) for either Wegovy or Saxenda, and the relationship appears complex and multifactorial
FEBS Open Bio 14 , 13651377 (2024)